Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

BioNTech’s stronger financial position and pipeline of complementary products give it a strategic edge. With several key data updates expected in 2025, the stock appears well-positioned for long ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

The research products are complex entities and there are many patents involved in a single product. That is why, BioNTech has ...

including its COVID-19 vaccine and other potential combo products, from Jan. 1, 2024. Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...